Innate Pharma Dirección

Dirección controles de criterios 4/4

El CEO de Innate Pharma's es Herve Brailly, nombrado en Jan 1999, tiene una permanencia de 25.25 años. posee directamente un 0.92% de las acciones de la empresa, con un valor de €1.65M. La antigüedad media del equipo directivo y de la junta directiva es de 4.1 años y 5.4 años, respectivamente.

Información clave

Herve Brailly

Chief Executive Officer (CEO)

€100.0k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	25.3yrs
Participación del CEO	0.9%
Permanencia media de la dirección	4.2yrs
Promedio de permanencia en la Junta Directiva	5.5yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Herve Brailly (62 yo)

25.3yrs

Permanencia

€100,000

Compensación

Dr. Herve Brailly, Ph.D. Co-Founded Innate Pharma S.A in 1999 and served as its Chairman of Supervisory Board since December 31, 2016 until January 1, 2024 and serves as its Interim CEO and Chairman of the...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Herve Brailly	Co-Founder	25.3yrs	€100.00k	0.92% € 1.7m
Yannis Morel	Executive VP	9yrs	€599.92k	0.24% € 438.9k
François Romagné	Founder	no data	sin datos	sin datos
Eric Vivier	Founder	6.3yrs	sin datos	0.26% € 475.1k
Marc Bonneville	Founder	no data	sin datos	sin datos
Jean Fournié	Founder	no data	sin datos	sin datos
Alessandro Moretta	Founder	no data	sin datos	sin datos
Frederic Lombard	Senior VP & CFO	3.1yrs	sin datos	0.014% € 25.7k
Sonia Quaratino	Executive VP	less than a year	sin datos	sin datos
Arvind Sood	Executive VP	less than a year	sin datos	sin datos
Henry Wheeler	Vice President of Investor Relations & Communication	1.3yrs	sin datos	0.0039% € 7.2k
Odile Belzunce	Vice President of Compliance & Operations	5.3yrs	sin datos	0.077% € 140.7k

4.2yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0EVI se considera experimentado (4.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Mario Sznol	Strategic Advisory Board Member	5.5yrs	sin datos	sin datos
Olivier Martinez	Member of Supervisory Board	no data	sin datos	sin datos
Ruslan Medzhitov	Strategic Advisory Board Member	5.5yrs	sin datos	sin datos
Gilles Brisson	Independent Member of Supervisory Board	16.9yrs	€29.00k	0.090% € 165.1k
Jean-Yves Blay	Independent Member of Supervisory Board	6.4yrs	€29.00k	0.000060% € 109.6
Irina Staatz-Granzer	Independent Chairwoman of Supervisory Board	14.9yrs	€42.00k	0.031% € 56.7k
Pascale Boissel	Independent Vice Chairperson of the Supervisory Board	4yrs	€60.00k	0.0012% € 2.3k
Miriam Merad	Chairman of Strategic Advisory Board	5.5yrs	sin datos	sin datos
Veronique Chabernaud	Independent Member of Supervisory Board	9.1yrs	€48.00k	0.00082% € 1.5k
Sebastian Amigorena	Strategic Advisory Board Member	5.5yrs	sin datos	sin datos
Aurelien Marabelle	Strategic Advisory Board Member	5.5yrs	sin datos	sin datos
Tanguy Seiwert	Strategic Advisory Board Member	5.5yrs	sin datos	sin datos

5.5yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de 0EVI se considera experimentada (5.4 años de antigüedad promedio).

Innate Pharma Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma S.A. Announces Executive Changes

Innate Pharma S.A. Announces Supervisory Board Changes

Innate Pharma S.A., Annual General Meeting, May 28, 2021

Innate Pharma S.A. Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome

Recent updates

Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Forecast to breakeven in 2026

Full year 2023 earnings released: €0.094 loss per share (vs €0.73 loss in FY 2022)

Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s Lymphoma

Innate Pharma S.A. has filed a Follow-on Equity Offering in the amount of $75 million.

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

New minor risk - Share price stability

Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023

Innate Pharma S.A. to Report Q2, 2024 Results on Sep 12, 2024

Innate Pharma S.A. Provides Update on Lacutamab Clinical Program

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

First half 2023 earnings released: EPS: €0.021 (vs €0.08 in 1H 2022)

Innate Pharma S.A. Announces Executive Changes

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung Cancer

Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen Criteria

Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 Congress

Innate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

No longer forecast to breakeven

Innate Pharma SA Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

Innate Pharma S.A. Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022

Innate Pharma S.A. to Report First Half, 2023 Results on Sep 14, 2023

Innate Pharma SA Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides

First half 2022 earnings released: EPS: €0.08 (vs €0.30 loss in 1H 2021)

Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

Innate Pharma S.A. Announces Supervisory Board Changes

Innate Pharma Sa Announces the First Patient Was Dosed in A Phase 1/2 Clinical Trial

Innate Pharma SA Announces That Data from the Phase 2 Expansion Cohort

First half 2021 earnings released: €0.30 loss per share (vs €0.13 loss in 1H 2020)

Innate Pharma SA Announces Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pneumonia

Innate Pharma Presents Preliminary Data from TELLOMAK Trial Showing Clinical Response for Lacutamab in Mycosis Fungoides

Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual Meeting

Innate Pharma S.A. Announces New Lacutamab Data from Tellomak Trial in Oral Presentation at Upcoming 16th International Conference on Malignant Lymphoma

Member of Supervisory Board Marcus Schindler has left the company

Full year 2020 earnings released: €0.81 loss per share (vs €0.31 loss in FY 2019)

Full year 2020 earnings released

Innate Pharma S.A. Advances Lacutamab Clinical Development Program

Innate's First NK Cell Engager Selected by Sanofi as Drug Candidate for Development

Rosen Law Firm Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action

Innate Pharma S.A., Annual General Meeting, May 28, 2021

Innate Pharma Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome

Innate Pharma S.A. Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome

Innate Pharma Launches HopeConnectLearn: A New Online Resource for Hairy Cell Leukemia Patients

New 90-day low: €3.10

New 90-day low - €3.70

First half earnings released

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad